Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...
The National Medical Product Administration (NMPA) has granted marketing approval for anaprazole, a proton pump...
Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...
US-based Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced that the U.S. Food and Drug Administration...
Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...
China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National...
The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...
China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...
The National Medical Products Administration (NMPA) has granted marketing approval to Shanghai Magic Medicine’s multimodal...
The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...
The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...